Toripalimab Combined With SBRT for NSCLC

NCT06293690 | Active Not Recruiting Phase 2

• 1 other identifier: L23-407
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC

Conditions

Non-small Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Major pathological remission rate

  The percentage of residual live tumor cells in the tumor bed after neoadjuvant therapy is ≤ 10%, regardless of whether there are residual live tumor cells in the lymph nodes.

  30 day

Secondary Outcomes (3)

• Complete pathological remission rate

  30 day

• disease-free survival（DFS）

  3 years

• overall survival

  3 years

Other Outcomes (1)

• Adverse events

  24 hours

Study Arms (2)

SBRT combined with immunochemotherapy

OTHER

A: Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.

Drug: Toripalimab

SBRT combined with immunotherapy

OTHER

B:Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3) on the second day. Two cycles in total.

Drug: Toripalimab

Interventions

Toripalimab DRUG

Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.

Also known as: SBRT, platinum-containing dual drugs

SBRT combined with immunochemotherapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age range from 18 to 75 years old, regardless of gender;
• ECOG behavior status score 0-1 points;
• Non small cell lung cancer diagnosed pathologically and clinically classified as stage IIA-IIIB (8th AJCC staging standard);
• Sufficient tumor tissue can be provided for biomarker analysis;
• Patients with distant metastasis are excluded through CT or PET/CT, and their physical condition is evaluated as acceptable for radical lung cancer surgery;
• Primary lung lesions are suitable for SBRT treatment;
• Confirming the absence of EGFR/ALK/ROS-1 sensitive gene mutations through molecular pathological diagnosis of the organization;
• The main organ functions within 7 days before the first administration meet the following standards:
• a Bone marrow function: hemoglobin ≥ 10.0 g/dL (no blood transfusion received within 28 days before hemoglobin test), absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L (no platelet transfusion or IL-11 treatment received within 14 days prior to platelet count test);b Coagulation function: INR and PT\<1.5 × ULN, APTT ≤ 1.5 × ULN;c Liver function: transaminases (ALT and AST) ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 2.5 in subjects with Gilbert\'s syndrome or liver metastasis) × ULN);d Renal function: serum creatinine clearance rate ≥ 60 mL/min (calculated according to Cockcroft Fault formula);e Adequate lung function: According to the doctor\'s judgment, lung function can meet the requirements of thymectomy surgery.

You may not qualify if:

• Pathological findings indicate complex small cell lung cancer, etc;
• History of previous lobectomy surgery and previous experience with radiotherapy and chemotherapy;
• Patients with concurrent secondary primary cancer and a history of malignant tumors less than 5 years (excluding completely cured cervical carcinoma in situ or basal or squamous cell skin cancer);
• The patient has any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, etc.);
• Have active infection or active tuberculosis history requiring systemic treatment;
• Those who have combined the following active infectious diseases, including those who are highly positive for hepatitis, known human immunodeficiency virus (HIV) infections, and sexually transmitted diseases such as active syphilis;
• Those who are known to have or combine with other uncontrollable diseases and are unable to receive surgical treatment;
• Physical examination or clinical trial findings that researchers believe may interfere with the results or increase the risk of treatment complications for patients;
• Previous history of interstitial lung disease, drug-induced interstitial disease, or any clinically proven active interstitial lung disease, baseline CT scan reveals the presence of idiopathic pulmonary fibrosis; Uncontrolled large amounts of pleural or pericardial effusion;
• Unstable systemic comorbidities (active infection period, moderate to severe chronic obstructive pulmonary disease, poorly controlled hypertension, unstable angina, congestive heart failure, myocardial infarction occurring within 6 months, severe mental disorders requiring drug control, metabolic diseases of the liver, kidney or other organs, neuropsychiatric disorders such as Alzheimer\'s disease);
• History of congenital or acquired immunodeficiency diseases or organ transplantation;
• Have received any of the following treatments:a Previously received chemotherapy, anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs, or other drugs that synergistically inhibit T cell receptors such as CTLA-4, OX-40, and CD137; Received any investigational medication within 4 weeks prior to the first use of the investigational medication;b Simultaneously enroll in another clinical study, unless it is an observational (non-intervention) clinical study or an intervention clinical study follow-up;c Individuals who have received anti-tumor vaccines or have received live vaccines within 4 weeks prior to the first administration of the investigational drug;d Having undergone major surgery or severe trauma within 4 weeks before the first use of the investigational drug;

Sponsors & Collaborators

• Shanghai Pulmonary Hospital, Shanghai, China: lead

Study Sites (1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200000, China

Location

MeSH Terms

Interventions

toripalimab

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Administrative Director of Thoracic Surgery

Study Record Dates

• First Submitted: February 27, 2024
• First Posted: March 5, 2024
• Study Start: April 15, 2024
• Primary Completion: December 30, 2025
• Study Completion (Estimated): June 30, 2026
• Last Updated: December 18, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)